The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement

CHRO

PTHS

<p>合并后的公司计划于 2025 年 7 月推出 ZELSUVMI™，用于治疗传染性软疣感染。与合并的完成同时，合并后的公司完成了一项 5010 万美元的股权私募融资</p>

Pelthos Therapeutics 完成与 Channel Therapeutics 的合并，并成功完成 5010 万美元的私募融资